Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 5Terminated 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Risk Reduction Behavior 1Hot Flashes 1Breast Neoplasms 1

Interventions

pembrolizumab 436Carboplatin 321Nivolumab 287Cyclophosphamide 280Specimen Handling 257Cisplatin 251Paclitaxel 248Magnetic Resonance Spectroscopy 248Radiotherapy 217Gemcitabine 180Dexamethasone 180Biopsy 177durvalumab 166atezolizumab 148Rituximab 138Lenalidomide 134Doxorubicin 134Docetaxel 130Bevacizumab 129Ipilimumab 125Radiation 118Capecitabine 117Pemetrexed 112Oxaliplatin 112Etoposide 111Radiosurgery 108Fluorouracil 108venetoclax 106fludarabine 106Prednisone 97

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Interventional × Estrogens, Conjugated (USP) × Clear all
NCT04821141 2025-10-29

Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens

University of Kansas Medical Center

Phase 2 Active not recruiting
120 enrolled
Breast

Breast Neoplasms, Hot Flashes, Risk Reduction Behavior

Data powered by HemOnc (CC BY 4.0) Colophon âš¡